US FTC Approves Fresenius And NxStage Merger
The US Federal Trade Commission has finally approved Fresenius' $2bn acquisition of NxStage Medical. A complaint filed by the FTC in February 2019 claimed the deal would be anti-competitive.
You may also be interested in...
Market Intel: Large Providers Focus On Hemodialysis Home Care; New Incentive By Presidential Executive Order
Momentum is rising for patients with chronic kidney disease to be treated with hemodialysis in the comfort of their own home as opposed to traveling several days a week to a freestanding clinic. Manufacturers, government and payers are paving the way for a higher home-therapy adoption rate. That said, many patients remain unsuitable for home care and the large volume of water needed to operate hemodialysis can be logistically daunting.
In a move to expand its dialysis empire into the growing home hemodialysis and critical care markets, Fresenius Medical Care has inked a $2bn deal to acquire NxStage Medical.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.